Navigation Links
FDA Investigating Weight-Loss Drug Over Reports of Liver Damage
Date:8/25/2009

32 cases reported since orlistat came on market in 1999

TUESDAY, Aug. 25 (HealthDay News) -- As U.S. health officials announced Monday that they are investigating the weight-loss drug orlistat for possible incidents of liver damage, experts noted the drug might not even work well enough to warrant such potential risks.

Orlistat is available in the United States, both as a prescription product (Xenical) and as an over-the-counter medication (Alli).

Depending on the findings from the investigation, this could dramatically change the risk-benefit ratio of taking the drug, experts noted.

The weight loss gleaned from the drug is quite modest, about 5 kilograms, said Dr. Timothy Pfanner, an assistant professor of internal medicine at the Texas A&M Health Science Center College of Medicine and a gastroenterologist with Scott & White, in Temple, Texas.

"It's not a really effective drug. The benefit is not so great to begin with," he said, and additional risks might simply make the drug that much less attractive.

The other problem is that many obese people already have underlying liver problems, added Dr. Eugene Schiff, director of the Center for Liver Diseases at the University of Miami Miller School of Medicine.

"If they [the Food and Drug Administration] feel there is a subgroup, albeit a small one but a real one, that gets a serious liver injury, [that] often will be compounded by the fact they have underlying liver disease," he said. "It's very important that this be resolved quickly."

The issue is complicated by the fact that some patients are taking the drug in its over-the-counter form, meaning they are likely not being tracked and monitored by doctors for side effects.

At this point, there is no reason for consumers to stop taking the drug if they're already on it -- as long as they're using it as recommended -- and no reason for physicians to stop prescribi
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations
2. FDA Investigating Safety of Asthma Drug Xolair
3. DEA Will Play Hardball in Investigating Michael Jacksons Doctors
4. Forensic Expert Investigating Chinese Drywall Issue
5. FDA Investigating Salmonella-Tainted Pistachios
6. Investigating a community where smoking rates are double the national average
7. Investigating causes of asthma attacks: New sensor system monitors environmental exposure
8. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
9. Consumer Specialty Products Association Responds to European Study Investigating Spray Products and Asthma
10. UT Southwestern investigating hypothermic technique in treating pediatric head injuries
11. Study Finds Weight-Loss Surgery Safer Than Thought
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Investigating Weight-Loss Drug Over Reports of Liver Damage
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... University of Chicago, have been assessing the effectiveness ... which is commonly prescribed for treatment of bronchitis, ... allocated 150 adults with acute bronchitis to either ... cough syrup (liquid dextromorphan) and an albuterol inhaler. ...
... to a research, women who live at high altitudes ... after finding lower concentrations of hormones, which are important ... the mountainous areas. ,For comparison researchers looked at a ... ethnic origin who lived at just 150 m above ...
... feeding rats with black raspberries reduces the risk of colon ... fresh fruits and vegetables may reduce the risk of cancer. ... protective compounds that various types of produce contain. //The latest ... -and how they may reduce the risk of colon cancer. ...
... new research, implants to aid hearing loss are going down ... a quarter of all adults aged over 60 in the ... a hearing problem - an acoustic hearing aid. // ... middle ear which directly vibrates the surrounding bones. Researchers in ...
... men population, which evaluated more than 14,000 sperm samples, found ... numbers as well as their crucial ability to move or ... ozone level went up, the sperm concentration went down," said ... and gynecology at the University of Southern California's Keck School ...
... a gene which acts as a specific diagnostic marker ... analysis, which allows investigation of the activity of thousands ... called a-methylacyl-CoA racemase (AMACR) and it's never before been ... study, AMACR was found in over 90 per cent ...
Cached Medicine News:Health News:High Altitude ‘Speeds up ageing process 2Health News:Elevated Ozone Levels Hurt Sperm Count 2
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... data, competitor focus, and new drug-eluting technologies to drive ... according to Millennium Research Group WALTHAM, Mass., May ... European Markets for Peripheral Vascular (PV) Devices 2009 ... that treat lower extremity peripheral artery disease in Europe ...
... Results and additional analyses from the Phase II portion ... drug relaxin for the treatment of acute heart failure ... annual meeting of the Heart Failure Association of the ... Metra, M.D., professor of cardiology at the University of ...
Cached Medicine Technology:Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013 2Lower Extremity Peripheral Vascular Stent and Balloon Catheter Markets to Exceed $180 Million in Europe by 2013 3Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: